Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 100 results for bladder cancer

  1. URO17 for testing suspected bladder cancer

      Status ...

    Diagnostics guidance
    Topic selection

  2. Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

    In development [GID-TA10252] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  3. Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

    In development [GID-TA11233] Expected publication date: 04 June 2025

    Technology appraisal guidance
    In development

  4. Urinary incontinence and pelvic organ prolapse in women: management (NG123)

    This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.

    NICE guideline
    Last updated
    24 June 2019
    View recommendations

    Sections for NG123

  5. Urinary tract infections in adults (QS90)

    This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    15 February 2023
    View quality statements

    Sections for QS90

  6. What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?

    satisfaction for bladder cancer? Any explanatory notes(if applicable) The urological cancers grouping (which includes...

    Research recommendation
    Published
    9 June 2015

  7. Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA817

  8. Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  9. Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    Awaiting development [GID-TA11115] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Is primary radical cystectomy more effective than primary intravesical BCG (Bacille Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?

    Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?...

    Research recommendation
    Published
    9 June 2015

  11. In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of biomarkers enable patients to select more effective treatment, and improve their outcomes, compared with treatment selected without biomarkers?

    Recommendation ID NG2/4 Question In patients with muscle-invasive bladder cancer suitable for radical treatment, does the use of...

    Research recommendation
    Published
    9 June 2015

  12. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development [GID-TA11300] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Further research on electrically stimulated intravesical chemotherapy for nonmuscle-invasive bladder cancer should include randomised controlled trials compared withstandard care, which should report details of patient selection.

    electrically stimulated intravesical chemotherapy for nonmuscle-invasive bladder cancer should include randomised controlled trials...

    Research recommendation
    Published
    18 February 2019

  14. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development [GID-TA11336] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953

    Awaiting development [GID-TA11469] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development